1 / 36

Prof essor Barry Cookson

Prof essor Barry Cookson. Antimicrobial Stewardship Reflections on International Efforts. Division of Infection and Immunity, Univ. College London. ECDC AMR Strategy. Infection Prevention & Control. Antimicrobial Stewardship. Training/ Education: Professio-nals & Public.

aurek
Télécharger la présentation

Prof essor Barry Cookson

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Professor Barry Cookson Antimicrobial Stewardship Reflections on International Efforts Division of Infection and Immunity, Univ. College London

  2. ECDC AMR Strategy Infection Prevention & Control Antimicrobial Stewardship Training/ Education: Professio-nals & Public New Diagnostics, Antibiotics and Treatments Prioritisation of R&D & Interventions: Organisational & Behavioural AMR & AB Usage Surveillance International Collaboration

  3. 7) strengthened international collaboration with a wide range of governmental and non-governmental organisations, international regulatory bodies and others to influence opinion, galvanise support, and mobilise action to deliver the scale of change needed globally. Seven Key Areas

  4. 8 components of WHO Regional Strategy • Combined strategy on HAI and AMR and link to patient safety • Strengthen surveillance of HAI and combine AMR • Improve use of standardized surveillance methods and indicators, and process & progress indicators • Standardize guidelines and tools for infection control and prevention in health care settings, including AM drug use. • Move from individual projects to national programmes • Foster partnership with professional groups • Review research agenda, training needs and gaps • Political commitment, advocacy, resourcesPittet et al, Considerations for a WHO European strategy…. The Lancet Infectious Diseases 2005; 5: 242-250.

  5. Liam Donaldson WHO Patient Safety Sally Davies UK Representative WHO Executive 2014 AMR Strategy Champion? Kenneth Calman Clinical Governance & Total Quality Management

  6. The Healthcare Associated Infection and related AMR paradox: high burden but little action • Complex issue: with no immediate, easy solution • Requires multi disciplinary approaches:never easy • Control and Prevention seen as costly • Diffuse issue: Individual or Institutional or “Public Health” problem?

  7. Why the increased profile in the “00”s? • A Patient Safety Issue at last • WHO Global Patient Safety Alliance • Hand Hygiene • Surgical Site Infection • Antimicrobial Resistance (never progressed!) • DG SANCO funded European project Improving Patient Safety in Europe (IPSE) • International community & media views changed as a result of SARS & the Pandemic Flu threat • Crying wolf no longer: Armageddon organisms are evident globally

  8. “EUROPE” • 17 Old Member States (MS) • 10 New MS • EEA: European Economic Area addsIceland, Liechtenstein andNorway • EFTA: European Free Trade AssociationSwitzerland, Iceland, Liechtenstein and Norway • EU acceding countries: Croatia April 2013 See European Economic Areahttp://en.wikipedia.org/wiki/European_Free_Trade_Association#Current_members

  9. “In England (~2005) we make hospital acquired infection (HAI) rates publically available by named hospital” After the initial shock around Europe: in 2012 6/28 European countries are doing this!

  10. Publication of hospital specific HAI infection ratesCookson et al, J Hosp Infect 2011: 79; 260-264 EU Directorate (SANCO) group suggested possibility of different systems: Confidential within the health care institution, not public health authorities e.g. individual surgical team infection rates. Confidential benchmarking within surveillance networks with publication of anonymised or aggregated results e.g. surveillance of surgical site infections. Disclosure to public health authorities e.g. early warning of notifiable nosocomial events. Public reporting of agreed indicators e.g. composite structure and process indicators or HAI rates e.g. France, England Vive la Différence

  11. Consensus standards and performance indicators for healthcare associated infection in EuropeCookson et al, J Hosp Infect 2011: 79; 260-264 Overall Averages80% 11% 2% 3%

  12. Seven Key Areas 2) optimising prescribing practice through implementation of antimicrobial stewardship programmes that promote rational prescribing and better use of existing and new rapid diagnosticsBehaviours of patients and doctors(Agricultural, Aquaculture, Vets use: science, politics and economic hurdles: overwhelmingly important!)

  13. ECDC Activities (Council Recommendation2002/77/EC) • 2013 !!! Exploring misuse of antimicrobial agents in human medicine across whole chain of stakeholders : prescribers, pharmacists and patients. Sales of antimicrobial agents without a prescription (SCORE 2002-03) • 2014: Antibiotic Prescribing & Resistance in European Children (ARPEC) • 2014-15: Follow up review of EC Recommendations

  14. Seven Key Areas • improving infection prevention and control practices in human (and animal health), both through enhanced dissemination & implementation of best practice & better use of data and diagnostics 5) better access to and use of surveillance data..facilitate greater data consistency & standardisation across the system & encourage improved data linkage

  15. Relevant DG SANCOEU Networks HELICS Hospitals in Europe Link for Infection Control through Surveillance • EARSS:European Antimicrobial Resistance Surveillance Scheme • ESAC:European • Surveillance of • AntimicrobialConsumption 2000 unofficial 1993 2002 ECDC Embedded in Improving Patient Safety in Europe (IPSE) 2005 HELICS2008

  16. C section (n= 12 124)HELICS-associated national networks (2000-2003) SSI rate per 100 op. Anonymised Countries

  17. Large differences are found between countries • in rates of HAIs, • in distribution of rates • in the characteristics of the infections This is attributable to: • Differences in definition interpretation/data collection? • Differences in recruitment? • Difference in Antibiotic Rx & other medical policies? • Difference in the quality of care?

  18. Healthcare-Associated Infections surveillance Network (HAI-Net) Coordination Groups (European experts) and contact points in participating countries Modules: Surgical site infections: 16 countries HAI in intensive care units: 14 countries Point prevalence survey: 30 countries HAI in long-term care (HALT-2, outsourced): 24 countries Surveillance of C. difficile infections, pilot: 14 countries Concordance of definitions, Validation studiesNeed post discharge

  19. Five Countries Reporting Hip Prosthesis Infections to ECDC have shown reduced infection rate trends between 2004-06 Source: HELICS-SSI, ECDC Annual Epidemiological Report 2008

  20. Methicillin-resistant Staphylococcus aureus EU 2005- 2007 EARSS-ECDC No. of countries 0 10 20 30 40 50 MRSA (%)  2 Countries with a significant increase (2005–2007)  8 Countries with a significant decrease (2005–2007)

  21. Alcohol hand rub consumption in acute care hospitals, ECDC PPS 2011-2012

  22. Structure and process indicators: percentage of single room beds *Poor data representativeness Single room beds in participating hospitals (%): median = 11.1% Source: ECDC, 2012 (ECDC PPS data as of 23/11/2012)

  23. Prevalence of antimicrobial use in acute care hospitals, ECDC PPS 2011-2012 *Poor PPS data representativeness

  24. Seven Key Areas 3) improving professional education, training and public engagement

  25. 2013 COMPETENCY 1: Infection Prevention &Control COMPETENCY 2: Antimicrobial resistance & antimicrobials COMPETENCY 3: Prescribing antimicrobials COMPETENCY 4: Antimicrobial Stewardship COMPETENCY 5: Monitoring and learning https://www.gov.uk/government/publications/antimicrobial-prescribing-and-stewardship-competencies

  26. Training HALT eBug

  27. Seven Key Areas 4) developing new drugs, treatments and diagnostics(and infection prevention and control interventions) 6) better identification and prioritisation of AMRresearch needs e.g. new drugs, improved rapid or point-of-care diagnostic tests for humans (& animals).

  28. Relevant DG R&D Projects      HARMONY (1999-2001) incl MRSA typing networkHarmonisation of Antibiotic Resistance measurement, Methods of typing Organisms and ways of using these and other tools to increase the effectiveness of Nosocomial infection control ARPAC (2002-2005) Very useful papers Antibiotic Resistance Prevention and Control ARMed (2002-2006) Antibiotic Resistance in Mediterranean Countries MOSAR (2007-2012) Mastering hOSpital Antimicrobial Resistance in Europe HARMONY    

  29. BURDEN 2008-2013 Very useful data Burden of Resistance and Disease in Europe • IMPLEMENT 2008-2013 (www site?)Implementing Strategic Bundles for Infection Prevention & Management. • PROHIBIT 2008-2013 Analyses existing guidelines and IPC practices • SATURN 2010-2015 Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria • R-GNOSIS 2011-2016Studies in Multidrug-resistant GNRs

  30. Other Ongoing Projects • " Routine diagnostic tool for urinary tract infections caused by extended spectrum beta lactamase and carbapenamase producing bacteria" (ROUTINE) • "Rapid identification of respiratory tract infections (RID-RTI) • "Development of a handheld antibacterial drug resistance diagnostic device using nanowire technology" (NANOMAL) • "Automated next generation sequencing for diagnostic microbiology“ (PATHSEEK),

  31. HORIZON 2020 • HEALTH.2013.2.3.1-1: Drugs and vaccines for infections that have developed or are at the risk of developing significant anti-microbial resistance. • HEALTH.2013.2.3.1-2: Stratified approaches to antibacterial and/or antifungal treatment

  32. A “Perfect Storm” • Companies withdrawing from antimicrobial market as: • New drug development expensive • Resistance, not just side effects, a huge challenge • Patient numbers often relatively small & regimens short • Patents short-lived

  33. Founded in 2007 Spreading the costs of R&D

  34. IMI New Drugs for Bad Bugs (ND4BB) initiative COMbatting BACterial resistance in Europe (COMBACTE) €194.6m “CLIN-Net”: large clinical trials “LAB-Net”: microbial surveillance for trial site selection • Studies : Novel antibiotic vs skin and respiratory infections New human immunoglobulin monoclonal antibody against S. aureus alpha toxin Molecular basis of the bacterial cell wall permeability (TRANSLOCATION) €29.3m • Explore how to stop the Gram negative bacteria ejecting antimicrobials

  35. Trans Atlantic Task Force Recommendations Future Collaborations (1)

  36. Trans Atlantic Task Force Recommendations Future Collaborations (2)

More Related